Agentix (AGTX) Operating Income (2013 - 2026)
Agentix's (AGTX) quarterly Operating Income came in at -$54285.0 in Q1 2026, up 68.46% YoY from -$32224.0 in Q1 2025, and up 19.53% on a QoQ basis from -$67463.0 in Q4 2025.
Agentix (AGTX) Operating Income (2013 - 2026) Analysis & Trends
Agentix (AGTX) has 14 years of Operating Income data on file, last reported at -$54285.0 in Q1 2026.
- Quarterly Operating Income rose 68.46% year-over-year to -$54285.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$445187.0 (up 13.26% YoY) and the FY2026 annual result came in at -$445187.0, up 13.26% from the prior year.
- Operating Income climbed to -$54285.0 in Q1 2026, from -$67463.0 in the prior quarter.
- In the past five years, Operating Income ranged from a high of $25326.0 in Q1 2024 to a low of -$2.0 million in Q1 2022.
- A 5-year average of -$299550.2 and a median of -$164654.0 in 2022 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income jumped 105.9% — and 2025, when it slumped 779.62%.
- Tracing AGTX's Operating Income over 5 years: stood at -$353638.0 in 2022, then soared by 95.52% to -$15846.0 in 2023, then tumbled by 510.97% to -$96815.0 in 2024, then soared by 30.32% to -$67463.0 in 2025, then climbed by 19.53% to -$54285.0 in 2026.
- The last three Operating Income figures came in at -$54285.0 (Q1 2026), -$67463.0 (Q4 2025), and -$123097.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 133.12 Mn |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | -95,504.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -95,504.00 |
| Mar 31, 2026 | -54,285.00 |
| Dec 31, 2025 | -67,463.00 |
| Sep 30, 2025 | -123,097.00 |
| Jun 30, 2025 | -200,342.00 |
| Mar 31, 2025 | -172,121.00 |
| Dec 31, 2024 | -96,815.00 |
| Sep 30, 2024 | -93,010.00 |
| Jun 30, 2024 | -151,305.00 |
| Mar 31, 2024 | 25,326.00 |
| Dec 31, 2023 | -15,846.00 |
| Sep 30, 2023 | -353,155.00 |
| Jun 30, 2023 | -401,135.00 |
| Mar 31, 2023 | -429,134.00 |
| Dec 31, 2022 | -353,638.00 |
| Sep 30, 2022 | -424,330.00 |
| Jun 30, 2022 | -164,654.00 |
| Feb 28, 2022 | -2.02 Mn |
| Nov 30, 2021 | -166,750.00 |
| Aug 31, 2021 | -244,105.00 |